The evolving treatment landscape in immune thrombocytopenia

Dr Hanny Al-Samkari - Massachusetts General Hospital, Boston, USA
The evolving treatment landscape in immune thrombocytopenia ( Dr Hanny Al-Samkari - Massachusetts General Hospital, Boston, USA )
25 Jun 2026

Highlights from APCCC 2026

Dr Natalia Gandur - Instituto de Oncología 'Ángel H. Roffo', Buenos Aires, Argentina
Highlights from APCCC 2026 ( Dr Natalia Gandur - Instituto de Oncología 'Ángel H. Roffo', Buenos Aires, Argentina )
24 Jun 2026

ASCO 2026: Updates in bladder cancer

Dr Natalia Gandur - Instituto de Oncología 'Ángel H. Roffo', Buenos Aires, Argentina
ASCO 2026: Updates in bladder cancer ( Dr Natalia Gandur - Instituto de Oncología 'Ángel H. Roffo', Buenos Aires, Argentina )
24 Jun 2026

ASCO 2026: Updates in renal cancer

Dr Natalia Gandur - Instituto de Oncología 'Ángel H. Roffo', Buenos Aires, Argentina
ASCO 2026: Updates in renal cancer ( Dr Natalia Gandur - Instituto de Oncología 'Ángel H. Roffo', Buenos Aires, Argentina )
23 Jun 2026

Mezigdomide plus carfilzomib dexamethasone improves PFS in R/R multiple myeloma

Prof Meletios Dimopoulos - National and Kapodistrian University of Athens, Athens, Greece
Mezigdomide plus carfilzomib dexamethasone improves PFS in R/R multiple myeloma ( Prof Meletios Dimopoulos - National and Kapodistrian University of Athens, Athens, Greece )
20 Jun 2026

Venetoclax azacitidine achieves MRD clearance and enables transplant in NPM1 mutated AML with molecular failure

Dr Chiara Sartor - University of Bologna, Bologna, Italy
Venetoclax azacitidine achieves MRD clearance and enables transplant in NPM1 mutated AML with molecular failure ( Dr Chiara Sartor - University of Bologna, Bologna, Italy )
20 Jun 2026

DVRd improves MRD negativity and PFS in transplant ineligible newly diagnosed multiple myeloma

Dr Saad Usmani - Memorial Sloan Kettering Cancer Center, New York City, USA
DVRd improves MRD negativity and PFS in transplant ineligible newly diagnosed multiple myeloma ( Dr Saad Usmani - Memorial Sloan Kettering Cancer Center, New York City, USA )
20 Jun 2026

Anselamimab reduces mortality and cardiovascular hospitalisation in kappa light chain AL amyloidosis

Prof Ashutosh Wechalekar - University College London Hospitals, London, UK
Anselamimab reduces mortality and cardiovascular hospitalisation in kappa light chain AL amyloidosis ( Prof Ashutosh Wechalekar - University College London Hospitals, London, UK )
19 Jun 2026

CD19 CD22 bispecific CAR T cell therapy achieves high response rates in R/R large B cell lymphoma

Prof Liang Wang - Beijing Tongren Hospital, Beijing, China
CD19 CD22 bispecific CAR T cell therapy achieves high response rates in R/R large B cell lymphoma ( Prof Liang Wang - Beijing Tongren Hospital, Beijing, China )
19 Jun 2026

Subcutaneous blinatumomab plus TKI drives high remission in relapsed Ph+ acute lymphoblastic leukaemia

Prof Elias Jabbour - The University of Texas MD Anderson Cancer Center, Houston, USA
Subcutaneous blinatumomab plus TKI drives high remission in relapsed Ph+ acute lymphoblastic leukaemia ( Prof Elias Jabbour - The University of Texas MD Anderson Cancer Center, Houston, USA )
18 Jun 2026

ATG vs PTCy for GVHD prophylaxis in AlloHCT shows improved survival in donor haematopoietic cell transplantation

Dr Johannes Schetelig - University Hospital TU Dresden, Dresden, Germany
ATG vs PTCy for GVHD prophylaxis in AlloHCT shows improved survival in donor haematopoietic cell transplantation ( Dr Johannes Schetelig - University Hospital TU Dresden, Dresden, Germany )
18 Jun 2026

Arsenic trioxide plus all trans retinoic acid improves QoL and reduces fatigue in high risk acute promyelocytic leukaemia

Prof Fabio Efficace - Italian Group for Adult Hematologic Diseases (GIMEMA), Rome, Italy
Arsenic trioxide plus all trans retinoic acid improves QoL and reduces fatigue in high risk acute promyelocytic leukaemia ( Prof Fabio Efficace - Italian Group for Adult Hematologic Diseases (GIMEMA), Rome, Italy )
18 Jun 2026